Head-to-head · certain cash vs the insurance bet

NexLife vs Ro: a sure $1,668 against a coverage gamble

These two barely sell the same product. NexLife sells a known year: compounded tirzepatide at an audited $139 a month, $1,668 all-in, dose-proof. Ro sells a process: prior-authorization navigation toward brand Zepbound or Wegovy, with hand-offs to LillyDirect at $349 or NovoCare at $499 when self-pay brand makes sense, and compounded options in reserve. Choosing between them is expected-value math about your insurance, not a price comparison.

Run your own numbers with one question: what are the honest odds your plan approves a GLP-1 prior authorization? If coverage clears, a brand copay year can undercut every compounded figure on this site while delivering the FDA-reviewed product — that outcome beats NexLife, and it is precisely what Ro's navigation exists to reach. If it fails, you have spent the waiting weeks to land on self-pay brand at $349–$499 a month — $4,188 to $5,988 a year — against a certain $1,668, and the gamble has cost you both time and money. High-odds coverage (documented BMI criteria, employer plans known to cover, prior approvals) argues Ro; cash-pay reality argues the audited certainty.

What each is not: NexLife is not FDA-reviewed medication — that is the compounded trade stated plainly. Ro is not a price; it is a pathway whose value collapses to its approval rate. And the honest hybrid exists: start at the audited $139 today, let a Ro-style authorization run in parallel, and switch to brand the day coverage clears — the 30-day exit makes that plan cheap to hold.

NexLife — the certain $139 ↗ Ro — run the insurance path ↗

Both are partner links with sponsored tags; the analysis precedes the links. How the money works.